BioCentury
ARTICLE | Distillery Therapeutics

Therapeutics: Interleukin-1 receptor accessory protein (IL-1RAP)

September 24, 2015 7:00 AM UTC

In vitro and mouse studies suggest anti-IL-1RAP antibodies could help treat AML. IL-1RAP is expressed by 80% of AML cells and correlates with poor prognosis. In primary AML cells, an antibody against IL-1RAP decreased interleukin-1 (IL-1)-mediated cell proliferation compared with a control antibody. In mice with AML xenografts, the antibody decreased leukemia cell numbers in peripheral blood, bone marrow and the spleen and increased survival. Next steps include planning for clinical testing of the antibody in 2016...